Cost Effectiveness of Pharmacotherapies for Attention-Deficit Hyperactivity Disorder

[1]  V. Sikirica,et al.  Cost Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Stimulant Compared with Stimulant Monotherapy for the Treatment of Attention-Deficit Hyperactivity Disorder in Children and Adolescents , 2012, PharmacoEconomics.

[2]  V. Sikirica,et al.  PIH23 Cost-Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Psychostimulant Compared to Psychostimulant Monotherapy for the Treatment of Attention Deficit/Hyperactivity Disorder in Children and Adolescents , 2011 .

[3]  D. Huse,et al.  Adult ADHD: prevalence of diagnosis in a US population with employer health insurance , 2011, Current medical research and opinion.

[4]  J. Thome,et al.  Pharmacological treatment of adult ADHD in Europe , 2011, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[5]  S. Dewilde,et al.  Methylphenidate delivery mechanisms for the treatment of children with attention deficit hyperactivity disorder: Heterogeneity in parent preferences , 2011, International Journal of Technology Assessment in Health Care.

[6]  V. Sikirica,et al.  PMH37 THE COST-EFFECTIVENESS OF GUANFACINE EXTENDED RELEASE (GXR) VERSUS ATOMOXETINE (ATX) FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS , 2011 .

[7]  D. Huse,et al.  Cost of illness and comorbidities in adults diagnosed with attention-deficit/hyperactivity disorder: a retrospective analysis. , 2011, The primary care companion for CNS disorders.

[8]  N. Halfon,et al.  Patterns of Comorbidity, Functioning, and Service Use for US Children With ADHD, 2007 , 2011, Pediatrics.

[9]  K. Föhr,et al.  Dose-dependent modulation of apoptotic processes by fluoxetine in maturing neuronal cells: an in vitro study , 2011, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[10]  S. Faraone,et al.  Predictors of persistent ADHD: an 11-year follow-up study. , 2011, Journal of psychiatric research.

[11]  D. Coghill The Impact of Medications on Quality of Life in Attention-Deficit Hyperactivity Disorder , 2010, CNS drugs.

[12]  M. Brams,et al.  Duration of effect of oral long-acting stimulant medications for ADHD throughout the day , 2010, Current medical research and opinion.

[13]  L. Davis,et al.  Atomoxetine and neuropsychological function in children with attention-deficit/hyperactivity disorder: results of a pilot study. , 2009, Journal of child and adolescent psychopharmacology.

[14]  Jason M. Fletcher,et al.  Long-Term Consequences of Childhood ADHD on Criminal Activities , 2009, The journal of mental health policy and economics.

[15]  J. Ioannidis,et al.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. , 2009, Journal of clinical epidemiology.

[16]  J. Buitelaar,et al.  The quality of life of children with attention deficit/hyperactivity disorder: a systematic review , 2009, European Child & Adolescent Psychiatry.

[17]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[18]  J. McGough,et al.  Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. , 2009, Journal of child and adolescent psychopharmacology.

[19]  Brent D. Fulton,et al.  Positive Association Between Attention-Deficit/ Hyperactivity Disorder Medication Use and Academic Achievement During Elementary School , 2009, Pediatrics.

[20]  T. Dilla,et al.  A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain , 2009, BMC psychiatry.

[21]  S. Bálint,et al.  Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis , 2009, British Journal of Psychiatry.

[22]  L. Habel,et al.  Mothers of Children Diagnosed With Attention-Deficit/Hyperactivity Disorder: Health Conditions and Medical Care Utilization in Periods Before and After Birth of the Child , 2009, Medical care.

[23]  J. Biederman,et al.  Long-Term, Open-Label Extension Study of Guanfacine Extended Release in Children and Adolescents with ADHD , 2008, CNS Spectrums.

[24]  J Ormel,et al.  The prevalence and effects of adult attention-deficit/hyperactivity disorder (ADHD) on the performance of workers: results from the WHO World Mental Health Survey Initiative , 2008, Occupational and Environmental Medicine.

[25]  M. Aristides,et al.  A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[26]  William E Pelham,et al.  The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. , 2007, Ambulatory pediatrics : the official journal of the Ambulatory Pediatric Association.

[27]  B. Horta,et al.  The worldwide prevalence of ADHD: a systematic review and metaregression analysis. , 2007, The American journal of psychiatry.

[28]  J. Buitelaar,et al.  Societal costs and quality of life of children suffering from attention deficient hyperactivity disorder (ADHD) , 2007, European Child & Adolescent Psychiatry.

[29]  L Eugene Arnold,et al.  Treatment for ADHD: is more complex treatment cost-effective for more complex cases? , 2007, Health services research.

[30]  D. Nutt,et al.  Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology , 2007, Journal of psychopharmacology.

[31]  M. Drummond,et al.  A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. , 2006, Health technology assessment.

[32]  T. Wilens,et al.  Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. , 2006, The Journal of pediatrics.

[33]  R. Kessler,et al.  The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. , 2006, The American journal of psychiatry.

[34]  Joseph Biederman,et al.  Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study , 2006, Psychological Medicine.

[35]  R. Weisler,et al.  An Interim Analysis of the Quality of Life, Effectiveness, Safety, and Tolerability (QU.E.S.T.) Evaluation of Mixed Amphetamine Salts Extended Release in Adults With ADHD , 2005, CNS Spectrums.

[36]  J. Swanson,et al.  Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD. , 2005, The American journal of psychiatry.

[37]  J. McGough,et al.  Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD. , 2005, Journal of the American Academy of Child and Adolescent Psychiatry.

[38]  T. B. Üstün,et al.  The Prevalence and Effects of Adult Attention Deficit/Hyperactivity Disorder on Work Performance in a Nationally Representative Sample of Workers , 2005, Journal of occupational and environmental medicine.

[39]  R. Kessler,et al.  Costs of attention deficit–hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000 , 2005, Current medical research and opinion.

[40]  V. Harpin,et al.  The effect of ADHD on the life of an individual, their family, and community from preschool to adult life , 2005, Archives of Disease in Childhood.

[41]  L. Matza,et al.  Health State Utilities for Childhood Attention-Deficit/Hyperactivity Disorder Based on Parent Preferences in the United Kingdom , 2005, Medical decision making : an international journal of the Society for Medical Decision Making.

[42]  J. Hay,et al.  Cost effectiveness of methylphenidate versus AMP/DEX mixed salts for the first-line treatment of ADHD , 2004, Expert review of pharmacoeconomics & outcomes research.

[43]  A. Klassen,et al.  Health-Related Quality of Life in Children and Adolescents Who Have a Diagnosis of Attention-Deficit/Hyperactivity Disorder , 2004, Pediatrics.

[44]  T. Vos,et al.  Cost-Effectiveness of Dexamphetamine and Methylphenidate for the Treatment of Childhood Attention Deficit Hyperactivity Disorder , 2004 .

[45]  H. Birnbaum,et al.  Attention-deficit/hyperactivity disorder: increased costs for patients and their families. , 2003, Journal of the American Academy of Child and Adolescent Psychiatry.

[46]  L. Annemans,et al.  A cost analysis of the management of attention-deficit/hyperactivity disorder (ADHD) in children in the UK , 2003 .

[47]  J. Biederman,et al.  Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. , 2002, The Journal of clinical psychiatry.

[48]  J. Swanson,et al.  A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. , 2002, Pediatrics.

[49]  T. Einarson,et al.  Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis. , 2001, Clinical therapeutics.

[50]  J. Wernicke,et al.  Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. , 2001, Pediatrics.

[51]  W. Pelham,et al.  Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. , 2001, Pediatrics.

[52]  R. Milne,et al.  Methylphenidate in children with hyperactivity: review and cost–utility analysis , 2001, Pharmacoepidemiology and drug safety.

[53]  S. Zubrick,et al.  The National Survey of Mental Health and Wellbeing: The Child and Adolescent Component , 2000, The Australian and New Zealand journal of psychiatry.

[54]  T O Jefferson,et al.  Guidelines for authors and peer reviewers of economic submissions to the BMJ , 1996, BMJ.

[55]  S. Faraone,et al.  Comorbidity of Diagnosis in Attention-Deficit Hyperactivity Disorder , 1992 .

[56]  M. Fischer,et al.  Assessment of Stimulant Response in ADHD Children Using a Refined Multimethod Clinical Protocol , 1991 .

[57]  P. Szatmari,et al.  Ontario Child Health Study: prevalence of attention deficit disorder with hyperactivity. , 1989, Journal of child psychology and psychiatry, and allied disciplines.

[58]  J. Kevill,et al.  ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents , 2012 .

[59]  R. Verma,et al.  Management of attention-deficit hyperactivity disorder , 2011, Journal of Pediatric Neurosciences.

[60]  Chika Akera,et al.  ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/ Hyperactivity Disorder in Children and Adolescents , 2011 .

[61]  H. Tobi,et al.  Long-Acting Methylphenidate-OROS in Youths with Attention-Deficit Hyperactivity Disorder Suboptimally Controlled with Immediate-Release Methylphenidate , 2008, CNS drugs.

[62]  D. De Graeve,et al.  Healthcare use, social burden and costs of children with and without ADHD in Flanders, Belgium. , 2006, Clinical drug investigation.

[63]  J. Buitelaar,et al.  Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. , 2006, European child & adolescent psychiatry.

[64]  J. Buitelaar,et al.  European clinical guidelines for hyperkinetic disorder – first upgrade , 2004, European Child & Adolescent Psychiatry.

[65]  P. Gillig,et al.  Attention-Deficit/Hyperactivity Disorder in Adults , 2004 .

[66]  K. Kavale,et al.  Impact of ADHD on school systems. , 2002 .

[67]  J. G. Gonzalez-Perez Developing a scoring system to quality assess economic evaluations , 2002, The European Journal of Health Economics.

[68]  F. Lynch,et al.  Variations in pharmacotherapy for attention deficit hyperactivity disorder in managed care. , 2001, Journal of child and adolescent psychopharmacology.

[69]  S. Paisley,et al.  The clinical effectiveness and cost-effectiveness of methylphenidate for hyperactivity in childhood: assessment report. NICE Technology Appraisal (TA13) , 2000 .